CORESTEMCHEMON Inc. (KOSDAQ:166480)

Market Cap	75.27B
Revenue (ttm)	26.49B
Net Income (ttm)	-16.89B
Shares Out	24.36M
EPS (ttm)	-728.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	166,274
Average Volume	210,667
Open	3,080.00
Previous Close	3,080.00
Day's Range	3,030.00 - 3,145.00
52-Week Range	2,600.00 - 15,610.00
Beta	0.92
RSI	59.53
Earnings Date	Aug 14, 2025

About CORESTEMCHEMON

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company was formerly known as Corest...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 355
• Stock Exchange: KOSDAQ
• Ticker Symbol: 166480

Financial Performance

In 2024, CORESTEMCHEMON's revenue was 28.76 billion, a decrease of -14.54% compared to the previous year's 33.66 billion. Losses were -26.25 billion, 48.6% more than in 2023.